icon- folder.gif   Conference Reports for NATAP  
  AIDS 2010
18th International AIDS Conference (IAC)
July 18-23 2010
Vienna, Austria
Back grey_arrow_rt.gif
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks
  Reported by Jules Levin
18th Intl AIDS Conference
July 18-23 2010 Vienna Austria
Judith Aberg, MD1, Turner Overton, MD2, Samir Gupta, MD3, Ron Falcon, MD4, Robert Ryan, MS5, Guy De La Rosa, MD4 1Bellevue Hospital Center at New York University, New York, NY, USA; 2Washington University School of Medicine, St. Louis, MO, USA; 3Indiana University School of Medicine, Indianapolis, IN, USA; 4Tibotec Therapeutics, Titusville, NJ, USA; 5Tibotec Inc, Titusville, NJ, USA


Figure 2. Lipid parameters at baseline and Week 12 In Figure 2A, dashed lines represent the National Cholesterol Education Program criteria12: Trig ≥150mg/dL, TC ≥200mg/dL, LDL ≥130mg/dL, HDL ≤40mg/dL for men and ≤50mg/dL for women; an=28; bn=27; cn=27; dTo convert from mg/dL to mmol/L, divide mg/dL value by the following conversion factors: Trig=88.6; TC, LDL or HDL=38.7. To convert apoA1 and apoB from mg/dL to g/L, divide by 100; DRV/r, darunavir/low-dose ritonavir; BL, baseline; Wk, week; ATV/r, atazanavir/low-dose ritonavir; Trig, triglycerides; TC, total cholesterol; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CI, confidence interval; Apo, apolipoprotein

aITT-observed (sample size varies by time point and parameter); ITT, intent-to-treat; DRV/r, darunavir/low-dose ritonavir; ATV/r, atazanavir/low-dose ritonavir; BL, baseline; Wk, week; CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin resistance; SD, standard deviation; IL, interleukin; hs-CRP, high sensitivity C-reactive protein; TNF-α, tumor necrosis factor-alpha; LPS, lipopolysaccharide